Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD
46.33
-0.43 (-0.93%)
Apr 13, 2026, 10:48 AM EDT - Market open
Market Cap113.67B -17.4%
Revenue (ttm)54.85B +5.5%
Net Income9.17B +40.5%
EPS7.48 +43.6%
Shares Out 1.21B
PE Ratio12.39
Forward PE9.48
Dividend$1.60 (3.46%)
Ex-Dividend DateMay 9, 2025
Volume411,704
Open46.35
Previous Close46.76
Day's Range46.06 - 46.47
52-Week Range43.32 - 55.73
Beta0.32
AnalystsBuy
Price Target58.00 (+25.2%)
Earnings DateApr 23, 2026

About SNY

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]

Sector Healthcare
Founded 1994
Employees 74,846
Stock Exchange NASDAQ
Ticker Symbol SNY
Full Company Profile

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 5 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $58.0, which is an increase of 25.20% from the latest price.

Price Target
$58.0
(25.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sanofi (SNY) Gains EU Approval for Dupixent in Young Patients with CSU

Sanofi (SNY) Gains EU Approval for Dupixent in Young Patients with CSU

3 hours ago - GuruFocus

Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced that the European Commission or EC has approved Dupixent or Dupilumab for the treatment of moderate-to-severe chronic spontaneou...

4 hours ago - Nasdaq

Sanofi (SNY) and Regeneron (REGN) Gain EU Approval for Dupixent in Young Children

Sanofi (SNY) and Regeneron (REGN) Gain EU Approval for Dupixent in Young Children

7 hours ago - GuruFocus

Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) on Monday said the European Commission has approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria (CSU) ...

9 hours ago - Nasdaq

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

9 hours ago - GlobeNewsWire

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is base...

9 hours ago - Benzinga

Sanofi (SNY) Gains Authorization for Nuvaxovid in Canada

Sanofi (SNY) Gains Authorization for Nuvaxovid in Canada

3 days ago - GuruFocus

Sanofi's Lunsekimig Shows Promise In Respiratory Diseases

(RTTNews) - Sanofi (SNY) announced that its investigational therapy Lunsekimig met both primary and key secondary endpoints in two Phase 2 studies targeting chronic respiratory conditions, underscorin...

6 days ago - Nasdaq

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

Sanofi SA (NASDAQ: SNY) on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, highlighting meaningful improvements in asthma and nasal polyp patien...

6 days ago - Benzinga

Sanofi: Lunsekimig Meets Primary, Key Secondary Endpoints In Phase 2 Respiratory Studies

(RTTNews) - Sanofi (SNY, SAN.PA) said phase 2 studies of lunsekimig in two chronic respiratory diseases met their primary and key secondary endpoints compared to placebo. In both studies, lunsekimig w...

6 days ago - Nasdaq

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Sanofi's lunsekimig met primary  and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES phase 2b study achieved its primary and key secondary endpoints in modera...

Other symbols: SNY
6 days ago - GlobeNewsWire

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate...

6 days ago - Benzinga

ACOFP: American College of Osteopathic Family Physicians Convenes Experts for Disease Prevention Summit

CHICAGO, IL / ACCESS Newswire / April 6, 2026 / On April 15, ACOFP, in collaboration with sponsors Sanofi and Merck, will gather 25 osteopathic family physicians in Orlando, Florida, for a focused ...

7 days ago - Finanz Nachrichten

Sanofi Receives EU Conditional Marketing Authorization For Rezurock In Chronic GVHD

(RTTNews) - Sanofi (SNY) has received conditional marketing authorization from the European Commission for Rezurock to treat chronic graft-versus-host disease in adults and in children aged 12 years a...

13 days ago - Nasdaq

Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock

(RTTNews) - Sanofi (SNY, SAN.PA) said the European Commission has granted a conditional marketing authorisation for Rezurock or belumosudil for the treatment of chronic graft-versus-host disease in ad...

13 days ago - Nasdaq

Sanofi: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new med...

13 days ago - Finanz Nachrichten

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medici...

Other symbols: SNY
13 days ago - GlobeNewsWire

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medici...

13 days ago - Benzinga

Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis

(RTTNews) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials—COAST 1, COAST 2, and SHORE—evaluating amlitelimab, a fully human non-T cell depleting monocl...

15 days ago - Nasdaq

Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dos...

15 days ago - Finanz Nachrichten

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Other symbols: SNY
15 days ago - GlobeNewsWire

EU regulator backs Sanofi's injectable version of blood cancer drug

French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the ​approval of a subcutaneous version of ‌its blood cancer drug administered through an on-body injector.

Other symbols: SNY
17 days ago - Reuters

Sanofi: CHMP Adopts Positive Opinion Recommending Approval Of Sarclisa

(RTTNews) - Sanofi (SNY, SAN.PA) announced the European Medicines Agencys Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of Sarclisa or isatuxi...

17 days ago - Nasdaq

Sanofi: Sanofi's Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

Sanofi's Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating...

17 days ago - Finanz Nachrichten

Sanofi (SNY) Gains Japanese Approval for Dupixent in Treating Bullous Pemphigoid

Sanofi (SNY) Gains Japanese Approval for Dupixent in Treating Bullous Pemphigoid

20 days ago - GuruFocus